Chimerix preclinical data

Chimerix reported data at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, D.C., providing preliminary evidence that brincidofovir resistance to adenovirus may be "slow to emerge" in humans. In vitro, the development of brincidofovir-resistant adenovirus required 2 mutations -- T87I and V303I -- in adenovirus polymerase to reduce the compound's activity by 4- to 8-fold. Furthermore, Chimerix said the mutations required >5 months of exposure to brincidofovir in cell culture before they emerged. ...